Trials / Withdrawn
WithdrawnNCT01806610
Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease
A Randomized, Placebo-controlled Trial of BPS804 on Safety and Tolerability in Patients With Late-stage Chronic Kidney Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ultragenyx Pharmaceutical Inc · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety, tolerability, and PK following a single administration of BPS804 in patients with chronic kidney disease stage 5D (CKD-5D) on hemodialysis.
Detailed description
This study was previously posted by Novartis and was transferred to Ultragenyx in February 2021.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPS804 | Single dose BPS804 administration. |
| DRUG | Placebo | Single dose placebo administration. |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2013-03-07
- Last updated
- 2022-09-14
Source: ClinicalTrials.gov record NCT01806610. Inclusion in this directory is not an endorsement.